EHA 2024 Recap: Optimizing the Relapsed/Refractory CLL Treatment Pathway

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.    Credit available for this activity expires: 07/31/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001409 ?ecd=bdc_podcast_libsyn_mscpedu